Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The purpose of this economic analysis was to develop an economic model using intra-institutional cost data for acute, oliguric renal insufficiency treated with either an albumin-furosemide complex or albumin followed by furosemide (sequential therapy). The perspective of this study was from the standpoint of the institution (University Medical Center, a teaching hospital). The decision tree and sensitivity analyses demonstrated that the albumin-furosemide complex would be more effective and less costly than sequential therapy for a range of outcome probabilities. Using effectiveness assumptions from published literature, the complex could avoid dialysis in 27% of patients compared with 8% of patients receiving sequential therapy. The complex would also be less costly ($7778 vs $8748). In terms of cost- effectiveness, the complex is $28,807 per averted dialysis compared with $109,350 for sequential therapy.

Original languageEnglish (US)
Pages (from-to)1380-1386
Number of pages7
JournalClinical Therapeutics
Volume21
Issue number8
DOIs
StatePublished - 1999

Keywords

  • Albumin
  • Dialysis
  • Economics
  • Furosemide
  • Renal insufficiency

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency'. Together they form a unique fingerprint.

Cite this